Posted by Michael Wonder on 23 Nov 2016
EMA publishes EPAR for Lartruvo
23 November 2016 - The EMA has published a EPAR for Eli Lilly's platelet derived growth factor receptor antagonist.
Lartruvo was approved by the European Commission on 9 November 2016 for use in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.
